ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2008
Pneumococcal vaccination and risk of myocardial infarction.
Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Influenza vaccination and the risk of myocardial infarction: a meta-epidemiology study.BMC public health · 2026Pooled it
- Vaccines for preventing pneumococcal infection in adults.The Cochrane database of systematic reviews · 2013Pooled it
- Safety and Efficacy of Simultaneous Inoculations of Pneumococcal and Influenza Vaccines in Patients with Coronary Artery Disease.Journal of atherosclerosis and thrombosis · 2021Trial
- The Risk of Adverse Cardiac Events after Pneumonia in Patients with Coronary Artery Disease.Annals of the American Thoracic Society · 2025Article
- Immunization and Cardiovascular Disease in Latin America. The CorVacc Study: Results.Global heart · 2025Observational
- Immunization and cardiovascular disease in Latin America. The CorVacc study: rationale and design.Archivos de cardiologia de Mexico · 2025Article
- Targeting gut microbiota to regulate the adaptive immune response in atherosclerosis.Frontiers in cardiovascular medicine · 2025Review
- Enabling Factors, Barriers, and Perceptions of Pneumococcal Vaccination Strategy Implementation: A Qualitative Study.Vaccines · 2022Article
- Effect of Pneumococcal Vaccine on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2022Review
- B Cells in Atherosclerosis: Mechanisms and Potential Clinical Applications.JACC. Basic to translational science · 2021Review
- Review
- Article
- [Pneumonia in old age].Der Pneumologe · 2021Review
- Infection and atherosclerosis: TLR-dependent pathways.Cellular and molecular life sciences : CMLS · 2020Review
- Seasonal and circadian patterns of myocardial infarction by coronary artery disease status and sex in the ACTION Registry-GWTG.International journal of cardiology · 2019Article
- Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations.Human vaccines & immunotherapeutics · 2018Review
- Vaccine against arteriosclerosis: an update.Therapeutic advances in vaccines · 2017Review
- Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions.JACC. Heart failure · 2017Review
- Higher risk for incident heart failure and cardiovascular mortality among community-dwelling octogenarians without pneumococcal vaccination.ESC heart failure · 2016Article
- Prevalence, pathogenesis, therapy, and prevention of cardiovascular events in patients with community-acquired pneumonia.Pneumonia (Nathan Qld.) · 2016Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBased on promising results from laboratory studies, we hypothesized that pneumococcal vaccination would protect patients from myocardial infarction.
methodsWe conducted a hospital-based case-control study that included patients considered to be at risk of myocardial infarction. We used health databases to obtain hospital diagnoses and vaccination status. We compared patients who had been admitted for treatment of myocardial infarction with patients admitted to a surgical department in the same hospital for a reason other than myocardial infarction between 1997 and 2003.
resultsWe found a total of 43 209 patients who were at risk; of these, we matched 999 cases and 3996 controls according to age, sex and year of hospital admission. Cases were less likely than controls to have been vaccinated (adjusted odds ratio [OR] 0.53, 95% confidence interval [CI] 0.40-0.70). This putative protective role of the vaccine was not observed for patients who had received the vaccine up to 1 year before myocardial infarction (adjusted OR 0.85, 95% CI 0.54-1.33). In contrast, if vaccination had occurred 2 years or more before the hospital admission, the association was stronger (adjusted OR 0.33, 95% CI 0.20-0.46).
interpretationPneumococcal vaccination was associated with a decrease of more than 50% in the rate myocardial infarction 2 years after exposure. If confirmed, this association should generate interest in exploring the putative mechanisms and may offer another reason to promote pneumococcal vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.